key: cord-0908701-lqtobbwx authors: Knorr, John; Colomy, Veronika; Mauriello, Christine; Ha, Seung title: Tocilizumab in patients with severe COVID‐19: a single‐center observational analysis date: 2020-06-17 journal: J Med Virol DOI: 10.1002/jmv.26191 sha: 4902b025f07a44ca02aae3916cf045768b51eb32 doc_id: 908701 cord_uid: lqtobbwx OBJECTIVE: Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an IL‐6 receptor antagonist, may be beneficial for severe COVID‐19, when cytokine storm is suspected. METHODS: This is a retrospective single‐center analysis of the records of patients diagnosed with COVID‐19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen‐support at 24, 48, and 72 hours, and 7, 14 and 28 days post‐tocilizumab, are reported. Patients were evaluated by baseline pre‐tocilizumab oxygenation status and changes in proinflammatory markers within seven days post‐tocilizumab are reported. RESULTS: Sixty‐six patients received tocilizumab at a mean dose of 724mg (7.4mg/kg), 3.7 days from admission. At baseline, 53% of patients were on ventilation support and all had elevated proinflammatory markers, including c‐reactive protein (CRP). Common comorbidities were diabetes mellitus (43%) and hypertension (74%). Most patients received concomitant glucocorticoids and hydroxychloroquine. Seven days after tocilizumab, ten patients (15.2%) had clinical improvement in their oxygenation status, and there was a 95% decrease in CRP. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients that received tocilizumab expired and 49% were discharged. CONCLUSION: This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID‐19. Clinical trials are ongoing to further evaluate tocilizumab's benefit in this patient population. This article is protected by copyright. All rights reserved. The earliest report of tocilizumab use in COVID-19 was published by Xu et al. They evaluated 21 patients and showed a decrease in CRP and oxygen intake, and most patients were discharged within 14 days post-tocilizumab. 11 A study in 15 patients by Luo et al showed decreased CRP and IL-6 levels in patients who received tocilizumab. 3 Alattar et al reported the results of 25 patients with a 14 day follow-up, showing a reduction in patients requiring invasive ventilation 14 days post-tocilizumab. 12 A study in 100 patients by Toniati et al showed clinical improvement in 77% of patients, 10 days after tocilizumab. 13 Although these reports have shown some clinical efficacy with tocilizumab use in patients with COVID-19 with presumed cytokine storm, others have reported a lack of benefit. 14-16 A study by Colaneri et al found that tocilizumab did not significantly affect admission to the intensive care unit or 7-day mortality in a cohort of 21 patients. 14 In a case study published by Radbel and colleagues, two patients with COVID-19, CRS, and secondary hemophagocytic lymphohistiocytosis had clinical decompensation, despite a decrease in IL-6 levels. 16 This retrospective single-center study reports on the outcomes of patients with severe COVID-19 who received tocilizumab at a large, urban medical center in the United States. This was a retrospective observational evaluation conducted at Einstein Medical Center Philadelphia and Einstein Medical Center Elkins Park of all patients with confirmed SARs-CoV-2 infection who were administered tocilizumab for COVID- 19 between March 25, 2020 and April 24, 2020. Tocilizumab was administered to patients who met criteria per hospital protocol: confirmed COVID-19, age ≥ 18 years, elevated D-dimer (> 1.5 mg/L), and interstitial pneumonitis. Prescribing was limited to a small number of designated pulmonary and infectious diseases physicians. Tocilizumab was dosed at 8 mg/kg with a maximum of 800 mg per dose, rounded to the nearest 200 mg vial size. The treatment protocol originally allowed for a maximum of three doses of tocilizumab if patients had no clinical improvement at least eight hours after the first dose. However, this was later modified to a maximum of one dose per patient due to limited availability, lack of supportive clinical data and high cost. Tocilizumab was reconstituted in 100 mL of 0.9% sodium chloride solution and administered intravenously over 60 minutes, according to package insert recommendations. 6 Data was collected via chart review at pre-tocilizumab baseline, and at 24 hours, 48 hours, 72 hours, 7 days, 14 days and 28 days post-tocilizumab. Data was collected through May 23, 2020 to allow for a 30-day follow-up for all patients, and all patients were followed through hospitalization. Study outcomes included clinical improvement and mortality 7 and 14 days after tocilizumab in the overall group, and between invasive ventilation and noninvasive ventilation groups. Clinical improvement was defined as discharge from the hospital, or a decrease of at least two oxygen-support categories on a modified ordinal scale as recommended by the WHO R&D Blueprint Group. 17 The scale consisted of the following categories: invasive ventilation defined as patients requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO); noninvasive ventilation defined as were made using the log rank test. Statistical analyses were made using GraphPad Prism version 8 software, and differences with two-sided p-values of <0.05 were considered statistically significant. A total of 66 patients received tocilizumab in this cohort. Of these, 18 (27.3%) were on mechanical ventilation at the time of their dose, and 48 (73.7%) were on non-invasive oxygen support or ambient air. Tocilizumab was given at a mean dose of 7.4 (±1.4) mg/kg [724 (±115) mg/dose], 3.7 (±2.9) days from admission. Seven patients in the noninvasive oxygen support group received two doses, and one patient in both groups received three doses. Age, weight, and sex distribution were comparable between groups. The majority of patients (77%) were black or African American with a median BMI of 32.8 kg/m 2 . Most patients (74.2%) had a past medical history of hypertension, 42.4% had diabetes, 16.7% had asthma or COPD, and 9.1% were immunocompromised. Baseline inflammatory markers, including D-dimer, ferritin, CRP, and LDH were elevated in the majority of patients, with median values significantly higher than the upper limit of normal. At baseline, procalcitonin and D-dimer levels were higher in the patients on invasive ventilation, but only the difference in procalcitonin was statistically significant (p=0.030 and p=0.064, respectively). Two-thirds of patients received at least one dose of concomitant steroids, and the majority of patients received hydroxychloroquine. All baseline characteristics are summarized in Table 1 At the time of this manuscript preparation, data supporting tocilizumab use was still limited to non-randomized studies. Xu et al evaluated outcomes in 21 patients with severe or critical COVID-19 infection. 11 Unlike the population presented in the current study, only 15% of their patients were on either invasive or noninvasive ventilation at baseline, whereas 53% of the population of this study was. 11 They found that 75% of their patients had decreased oxygen intake within five days of receiving tocilizumab and they reported no deaths. 11 Alattar et al reported on the results of 25 patients in the intensive care unit that were on mechanical or nonmechanical ventilation and found that the percentage of patients on invasive ventilation decreased by 67% within 14 days post-tocilizumab. 12 They reported that 36% of their patients were discharged from the ICU within 14 days, and 12% died. 12 Luo et al reported on 15 patients with COVID-19 with varying degrees of illness. 3 Overall, 47% of their patients were critically ill, however they did not report on patients' baseline oxygenation requirements. 3 They reported outcomes seven days post-tocilizumab. 3 Of their patients, three died by day seven, two had disease aggravation, nine were clinically stable, and one had clinical improvement. 3 Toniati et al reported on the outcomes of 100 patients with COVID-19 and hyperinflammatory syndrome. 13 They reported that 77% of patients had improvement in the Brescia COVID-19 Respiratory Severity Scale (BCRSS) 10 days after tocilizumab. Baseline ventilation status was not reported, but patients had a relatively low average BCRSS score of 3. This article is protected by copyright. All rights reserved. Colineri et al reported on outcomes of 21 patients with COVID-19 and found that treatment with tocilizumab did not significantly affect admission to an intensive care unit or 7-day mortality when compared to standard of care treatment. 14 The current study identified patients that worsened or died beyond seven days, indicating that five or seven days may be inadequate to assess for clinical outcome in COVID-19 as a result of tocilizumab. This study reports clinical outcomes and changes in oxygenation status at multiple time points up to 14 days post-tocilizumab, and mortality and clinical improvement through 28 days. In all studies including this one, most patients received a single dose of tocilizumab. However, patients in each of the previously described reports could have received up to three doses if there was insufficient clinical response as determined by their prescriber. 3, 11, 12 The protocol used in the patients of this study targeted a dose of 8 mg/kg, and the majority of patients received a dose of 800 mg. The mean time from admission to tocilizumab dose was 3.7 days. This is the same regimen used in the reports by Toniati et al and Colaneri et al. 13, 14 Toniati et al gave tocilizumab on average, 5 days after admission. 13 Alattar et al used a median dose of 5.7 mg/kg/dose, and reported a median time of one day from ICU admission to tocilizumab dose, and one day from hospital admission to ICU admission. 12 The cohort presented here had the highest mortality rate compared to the other published report. A greater proportion of patients in this study were on invasive ventilation at baseline, and there were high rates of hypertension and/or diabetes, known risk factors for mortality in adult patients with COVID-19. 3, [11] [12] [13] [14] 18 The patients in this study were largely of black race with a high incidence of obesity. Obesity has also been associated with increased COVID-19 disease severity and need for intensive care treatment. 19 The rate of hypertension at baseline was 74% and the rate of diabetes was 42%. Patient populations in previous studies reported rates of hypertension ranging from 43-60% and Accepted Article rates of diabetes ranging from 24-48%. 3, [11] [12] [13] The median D-dimer level in the current cohort was greater than 1 mg/L, which has been associated with increased mortality in patients with COVID-19. 18 Given the association of elevated IL-6 and inflammatory marker levels with COVID-19 disease severity, and the mechanism of tocilizumab as an IL-6 receptor antagonist, assessment of these laboratory values before and during therapy is reasonable. Luo et al found a reduction of IL-6 and CRP levels in their patients seven days after treatment with tocilizumab. 3 Xu et al did not find a reduction of IL-6 levels in the 5 days post dose. 11 Alattar et al reported a decrease in CRP by day seven, but not did not report IL-6 levels. 12 Ten days after tocilizumab administration, Toniati et al reported a decrease in CRP, fibrinogen and ferritin levels towards a normal range, however, D-dimer and IL-6 levels increased in both improved and worsened patients. 13 This suggests that not all inflammatory markers may be reduced by IL-6 antagonism. This study observed a 95% reduction in CRP levels from baseline in the 29 patients that had evaluable levels at baseline and 7 days post-tocilizumab, but levels of D-dimer, ferritin and LDH seemed relatively unchanged. In an analysis by overall clinical outcome, patients had similarly elevated baseline D-dimer, ferritin, CRP and LDH, regardless of their ultimate clinical status. IL-6 levels were not collected in this study due to the inability for the laboratory to measure these, and the turnaround time for results from an external laboratory would limit the result's utility in patient care. The main limitation of this study was that it was an observational, retrospective study that lacked a randomized control group. Additional limitations include a small sample size, which make it difficult to draw clear conclusions regarding the efficacy of tocilizumab. Per the treatment protocol, inclusion criteria for administration of tocilizumab was very broad, and included patients with severe COVID-19 and elevated D-dimer levels. This may have contributed to a selection bias towards patients with severe or advanced illness. Approximately two-thirds of patients received glucocorticoids and 83.3% received hydroxychloroquine. While the benefit of these agents in COVID-19 is still a matter of debate, there is potential confounding from concomitant application of multiple interventions. Routine laboratory monitoring was not included in the treatment protocol. This led to inconsistencies in the timing of laboratory orders, making it difficult to determine what impact tocilizumab may have had on inflammatory markers. Emerging literature has shown an association with elevated D-dimer levels and thrombotic events in patients with COVID-19, however, this was not evaluated in this study. 20 Lastly, this study did not assess for adverse drug reactions such as serious infections, which have been reported with tocilizumab use. 6 This study observed limited clinical improvement in patients that received tocilizumab in the setting of severe COVID-19. This study did not identify a difference in outcomes between patients who were on mechanical ventilation at baseline or non-invasive oxygen support. Given the paucity of supporting clinical evidence, tocilizumab may be best reserved for use in a randomized clinical trial, a recommendation supported by recently published practice guidelines. [7] [8] [9] Who Health Organization; 2020 2. Cases in the US Tocilizumab treatment in COVID-19: a single center experience Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinical features of patients infected with 2019 novel coronavirus in Wuhan Infectious Disease Society of America Guidelines on the Treatment and Management of Patients with COVID-19 COVID-19) Treatment Guidelines. National Institutes of Health National Health Commission and National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7) Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab for the treatment of severe COVID-19 Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020 Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-center retrospective cohort study Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome COVID-19 Therapeutic Trial Synopsis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study European Association for the Study of Obesity Position Statement on the Global COVID-19 Pandemic Coagulation abnormalities and thrombosis in patients with COVID-19 Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in /mL, median (IQR) IQR) Range 607 (502, 765) 246, 1044 563 (382, 708) 297 Tocilizumab dose, mean mg (SD)